Management of the lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with terazosin

Abstract

Objective: This study was designed to assess the efficacy, safety and compliance of terazosin in the management of lower urinary tract symptoms due to benign prostatic hyperplasia. Patients and methods: Study was conducted in the department of urology, DHQ Hospital Vehari, in about 1-year i-e from July 2004 to June 2005. Sixty patients with an age range of 45-85 years were included in the study. Data was collected prospectively. Patients were assessed according to the international prostate symptom score (I-PSS) at the start of study, during follow up and at the end of study. Results: Out of sixty patients, fifty-two were able to complete the study. It was observed that most of the patients obtained a significant decrease in the prostate symptoms score and improvement in QoL score, with only a few side effects. Conclusion: Terazosin is a safe and effective treatment for BPH with good compliance.